Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

this drop in the stock is still an unambiguously appealing opportunity to buy the dip. Overall, Vertex's data on the candidate's efficacy for general acute pain look better than the new data on ...

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

BMO Capital Markets boosted their price target on shares of Vertex from $42.00 to $52.00 and gave the stock a “market perform” rating in a research note on Thursday, November 7th. Morgan ...